Estats Units - anglès - NLM (National Library of Medicine)

par pharmaceutical - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - codeine phosphate 10 mg in 5 ml - promethazine vc with codeine oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in patients 18 years of age and older. important limitations of use - not indicated for pediatric patients under 18 years of age [see use in specific populations (8.4) ]. - contraindicated in pediatric patients under 12 years of age [see contraindications (4) and use in specific populations (8.4) ]. - contraindicated in pediatric patients 12 to 18 years of age after tonsillectomy or adenoidectomy [see contraindications (4) and use in specific populations (8.4) ]. - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve promethazine vc with codeine oral solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough h

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - methadone hydrochloride - oral tablet - 5mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - oxcarbazepine - oral suspension - 60mg/1ml

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - tipranavir - oral solution - 100mg/1ml

Estats Units - anglès - NLM (National Library of Medicine)

ucb inc. - hydrocodone (unii: 6yks4y3wq7) (hydrocodone - unii:6yks4y3wq7), chlorpheniramine (unii: 3u6io1965u) (chlorpheniramine - unii:3u6io1965u) - hydrocodone 10 mg in 5 ml - tussionex pennkinetic extended-release suspension is indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. important limitations of use: - not indicated for pediatric patients under 18 years of age [see use in specific populations (8.4) ]. - contraindicated in pediatric patients less than 6 years of age [see contraindications (4) ]. - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve tussionex pennkinetic for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. tussionex pennkinetic is contraindicated for: - all children younger than 6 years of age [see warnings and precautions (5.2, 5.3), use in specific populations (8.4) ]. tussionex pennkinetic is also contraindicated in patients with: -

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

novartis ireland limited - oxcarbazepine - oral suspension - 60 milligram(s)/millilitre - carboxamide derivatives; oxcarbazepine

Estats Units - anglès - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - promethazine with codeine oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. promethazine with codeine oral solution is contraindicated in pediatric patients less than 12 years of age. (see warnings - ultra- rapid metabolism of codeine and respiratory depression ). promethazine with codeine oral solution is contraindicated for post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy. (see warnings - ultra- rapid metabolism of codeine and respiratory depression ). codeine is contraindicated in patients with a known hypersensitivity to the drug. promethazine hydrochloride is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines and codeine are both contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. prom

Estats Units - anglès - NLM (National Library of Medicine)

remedyrepack inc. - oxcarbazepine (unii: vzi5b1w380) (oxcarbazepine - unii:vzi5b1w380) - trileptal is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. trileptal is contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate [ see warnings and precautions (5.2, 5.3) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aeds, such as trileptal, during pregnancy. encourage women who are taking trileptal during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. risk summary there are no adequate data on the developmental risks associated with the use of trileptal in pregnant

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

alkaloid - int d.o.o - methadone hydrochloride - oral solution - 1/1 milligram(s)/millilitre - methadone

Estats Units - anglès - NLM (National Library of Medicine)

atlantic biologicals corp. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), chlorpheniramine maleate (unii: v1q0o9oj9z) (chlorpheniramine - unii:3u6io1965u) - hydrocodone polistirex and chlorpheniramine polistirex extended-release suspension is indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. important limitations of use : • not indicated for pediatric patients under 18 years of age [see use in specific populations (8.4 ) ]. • contraindicated in pediatric patients less than 6 years of age [see contraindications (4) ]. • because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve hydrocodone polistirex and chlorpheniramine polistirex for use in adult patients for whomthe benefits of cough suppression are expected to outweigh the risks, and in whom an adequateassessment of the etiology of the cough has been made. hydrocodone polistirex and chlorpheniramine polistirex is contraindicated for: - all children younger than 6 years of age [see warnings and precautions (5.2 , 5.3 ),